Avid Bioservices Inc (CDMO)

[biopharm]

Kolltan and PS Targeting: Part II


1) Lemke Lab
http://www.lemkelab.org/

2) Projects = The Regulatory Logic of Signaling
http://www.lemkelab.org/index.php?option=com_content&view=article&id=46&Itemid=67

2a) We are currently studying the role that TAM RTKs play in the maintenance of cellular homeostasis in macrophages and dendritic cells and below link explains in detail....
http://www.lemkelab.org/index.php?option=com_content&view=article&id=50&Itemid=96

2b) We are particularly interested in the role that dysregulation of the TAM signaling network plays in (a) the development of autoimmune diseases such as Lupus, Multiple Sclerosis, and Rheumatoid Arthritis and below link explains in detail...
http://www.lemkelab.org/index.php?option=com_content&view=article&id=58&Itemid=105

2c) also (b) the course of infection by influenza, HIV, West Nile, and Dengue viruses and link below explains in detail...
http://www.lemkelab.org/index.php?option=com_content&view=article&id=52&Itemid=104

2d) and and (c) the organization and function of synapses in the central nervous system and link below explains in detail...
http://www.lemkelab.org/index.php?option=com_content&view=article&id=53&Itemid=99

2e) In a second project area, we are interested in how expression gradients of Eph receptors are established across fields of developing neurons, and how these interacting RTK gradients function during the topographic wiring of the eye to the brain. Current efforts are directed toward the analysis of a set of transcription factors (Vax proteins) that integrate the activities of the Sonic hedgehog and Wnt morphogen gradients that initially specify Eph receptor gradients in the embryonic nervous system and below link explains in detail...
http://www.lemkelab.org/index.php?option=com_content&view=article&id=54&Itemid=67



Now concentrating on 2b and that link that explains more we have = TAM receptor signaling and phagocytosis

Genetic studies have demonstrated that the TAM system is also required for the phagocytosis of apoptotic cells (ACs) by DCs and macrophages, and that the suppressive effects of ACs on DC and macrophage activation are almost entirely dependent on TAM receptor engagement2-4. TAM receptors are expressed on phagocytes. The TAM ligands Gas6 and Protein S (Pros1) bind to both TAM receptors on the surface of a phagocyte (through a C-terminal domain) and to the phospholipid phosphatidylserine (PtdSer) expressed on the surface of ACs (through an N-terminal ‘Gla domain’.) In this way, Gas6 and Pros1 ‘bridge’ an AC to the phagocyte that will engulf it. TAM action during the phagocytosis of ACs extends to other organ systems, including the nervous and reproductive systems. These activities have broad implications for the use of TAM-based therapies in the treatment of lupus and other autoimmune diseases, which are generally characterized by both chronic inflammation and defects in the phagocytic clearance of ACs. We are currently studying how Tyro3, Axl, and Mer phagocytic activities are differentially controlled by Gas6 and Pros1 in different phagocytes5-7, as well as the interaction of TAM receptors with other phagocytic clearance systems.

http://www.lemkelab.org/index.php?option=com_content&view=article&id=58&Itemid=105

-----------------------------------------------------

Greg Lemke : Taming the immune system (After watching this and reading all the work that Greg Lemke has put into this, and seeing Kolltan buying out the patents of Salks/Lemke patents..etc and then bringing Greg Lemke into Kolltan and why oh why does Greg enter UTSWM now ?? looks like PS Targeting is more important than the pessimists are seeing. Some like to say the pps is still at $1.xx well its been 100 years of research and we are right back at the beginning of understanding ones immune system

Aug 28, 2010

Taming the Immune System -- New discoveries in immune system regulation suggest novel therapies for autoimmune disease

----------------------------------------------------

Ice Bucket Challenge:

Greg Lemke

Steve King & Paul Lytle

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106201104